公司概述
Baxter International Inc. operates within the United States healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, where it delivers a comprehensive portfolio of healthcare products. Through its subsidiaries, the company executes its business model across three distinct segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, offering sterile intravenous (IV) solutions and infusions among other critical medical interventions. The firm employs approximately 37,500 people globally, reflecting a substantial operational footprint within the specialized medical device and supply chain ecosystem. With a market capitalization of $8.93 billion and annual revenue reaching $11.24 billion, Baxter demonstrates significant scale, positioning it as a major player capable of influencing pricing dynamics and supply chain resilience within the medical instruments sector.
财务健康
The company reported total revenue of $11.24 billion over the trailing twelve months, yet it recorded a net income of -$900,000,000, highlighting a severe divergence between top-line sales and bottom-line profitability. While EBITDA stands at $2.02 billion, the massive negative net income indicates that the cost structure is heavily impacted by significant non-operating expenses, interest costs, or other adjustments that erode the cash earnings generated from core operations. Despite the reported net loss, the firm generated free cash flow of $2.43 billion, which suggests that operational cash generation remains robust and provides a degree of financial flexibility to service obligations or fund capital expenditures. However, the gross margin sits at 35.7%, while the operating margin is 7.4%, contrasting sharply with the negative profit margin of -8.5%, revealing that while core production efficiency is maintained, broader financial factors are suppressing overall profitability. The balance sheet shows a cash position of $1.97 billion against total debt of $9.78 billion, resulting in a debt-to-equity ratio of 160.28%, which characterizes the company as highly leveraged with a conservative cushion that is currently strained by interest burdens. Liquidity is supported by a current ratio of 2.31, indicating that the company holds more than double the current assets required to cover its short-term liabilities, suggesting adequate short-term solvency despite the long-term debt load. Return on Equity is reported at -13.7% and Return on Assets at 2.8%, metrics that collectively indicate that management is currently unable to generate positive returns on shareholder capital or total assets, likely due to the heavy debt servicing costs mentioned in the net income analysis.
估值评估
Valuation metrics present a mixed picture, with the P/E Ratio (TTM) listed as N/A due to the net loss, while the Forward P/E stands at 8.54, implying that the market prices the stock based on anticipated future earnings recovery rather than current profitability. The price-to-book ratio is 1.45, suggesting that the market values the company at approximately 45% above its book value, which could reflect intangible assets or expectations of future cash flow generation despite current losses. Alternative valuation multiples such as the price-to-sales ratio of 0.79 and EV/EBITDA of 8.27 provide context, indicating that the stock trades at less than one dollar of revenue per share and has an enterprise value relative to earnings before interest, taxes, depreciation, and amortization that is lower than many mature peers. The stock's 52-week trading range spans from a low of $15.73 to a high of $32.68, and assuming a current price near the midpoint of this range, the security is trading significantly below its recent highs, reflecting market caution regarding the negative earnings profile. With a beta of 0.62, the stock exhibits lower volatility than the broader market, implying that its price movements are less sensitive to general market fluctuations, which may offer stability for risk-averse investors seeking exposure to the healthcare sector.
Growth & Income
Revenue growth year-over-year is recorded at 8.0%, demonstrating that the company is successfully expanding its top line, whereas earnings growth is N/A due to the current net loss, indicating that revenue expansion has not yet translated into improved profitability. The dividend yield is 2.1%, which appears attractive on the surface, but the payout ratio of 307.7% is unsustainable given the negative net income, signaling that the dividend is being funded from cash reserves or debt rather than retained earnings. This structural imbalance means that the company is not reinvesting earnings into growth for the purpose of dividend growth, as it is currently unable to grow dividends without external financing. Overall, the growth and income profile is characterized by strong revenue expansion and high cash flow generation that partially offsets the inability to sustain a dividend payout from current earnings, creating a complex investment scenario where income is decoupled from profitability.